BRIEF—New CEO to transform LEO Pharma

LEO Pharma has appointed Christophe Bourdon as chief executive officer, effective from April 1, 2022.

In a statement, the Danish dermatology specialist said it was “taking significant steps to transform the company to become a competitive, global player in the growing dermatology market, successfully launch a global product portfolio and prepare the company for a public listing (IPO).”

Mr Bourdon has been appointed to lead the company through this period of transformation. He joins LEO from Orphazyme, where he has been CEO since April 2021.

He has also held significant global leadership roles at both Amgen and Alexion.